55103-52-1

Basic information

• Product Name: 8-Ethoxy-1,4-dioxaspiro[4.5]decane
• Synonyms: 8-Ethoxy-1,4-dioxaspiro[4.5]decane;4-ETHOXYCYCLOHEXANONE ETHYLENE KETAL
• CAS NO: 55103-52-1
• Molecular Formula: C₁₀H₁₈O₃
• Molecular Weight: 186.25
• Mol File: 55103-52-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 8-Ethoxy-1,4-dioxaspiro[4.5]decane(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Ethoxy-1,4-dioxaspiro[4.5]decane(55103-52-1)
• EPA Substance Registry System: 8-Ethoxy-1,4-dioxaspiro[4.5]decane(55103-52-1)

Safety Data

• Hazardous Substances Data: 55103-52-1(Hazardous Substances Data)

Upstream product

• 22428-87-1 4,4-ethylenedioxycyclohexan-1-ol 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 637-88-7 1,4-Cyclohexanedione 

Downstream Products

• 23510-92-1 4-ethoxycyclohexan-1-one 
• 206435-95-2 4-ethoxy-2-cyclohexen-1-one 
• 192504-15-7 4-Ethoxycyclohexanon-2,2,6,6-d⁽⁴⁾ 
• 106421-17-4 ethyl-cyclohex-3-enyl ether 
• 106349-63-7 4-ethoxycyclohexan-1-ol 
• 192504-16-8 C₈H₁₅⁽²⁾HO₂ 
• 578717-93-8 4-ethoxycyclohexanecarbaldehyde 

Relevant articles and documents

IRAK INHIBITORS AND METHOD FOR MAKING AND USING

Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed c

PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.